BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38233113)

  • 1. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
    Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
    Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
    Park W; Wei S; Xie CL; Han JH; Kim BS; Kim B; Jin JS; Yang ES; Cho MK; Ryu D; Yang HX; Bae SJ; Ha KT
    Exp Mol Med; 2024 May; 56(5):1137-1149. PubMed ID: 38689087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
    Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
    Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.
    Li Y; Wang N; Huang Y; He S; Bao M; Wen C; Wu L
    Cancer Genet; 2024 Jun; 284-285():34-42. PubMed ID: 38626533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC).
    Tang YF; Liu ZH; Zhang LY; Shi SH; Xu S; Ma JA; Hu CH; Zou FW
    Mol Cancer; 2024 May; 23(1):91. PubMed ID: 38715012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38451729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
    Hu B; Wiesehöfer M; de Miguel FJ; Liu Z; Chan LH; Choi J; Melnick MA; Arnal Estape A; Walther Z; Zhao D; Lopez-Giraldez F; Wurtz A; Cai G; Fan R; Gettinger S; Xiao A; Yan Q; Homer R; Nguyen DX; Politi K
    Cancer Res; 2024 Apr; 84(8):1303-1319. PubMed ID: 38359163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip.
    Tan J; Zhu L; Shi J; Zhang J; Kuang J; Guo Q; Zhu X; Chen Y; Zhou C; Gao X
    Eur J Pharm Sci; 2024 Aug; 199():106805. PubMed ID: 38763450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
    Chen CY; Wang GS; Wei JC
    J Thorac Oncol; 2024 May; 19(5):e6-e7. PubMed ID: 38719427
    [No Abstract]   [Full Text] [Related]  

  • 10. The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
    Maione P; Salvi R; Gridelli C
    Curr Oncol; 2024 Feb; 31(2):987-997. PubMed ID: 38392068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.
    Matsuura H; Higo H; Kuribayashi T; Tamaoki A; Nakasuka T; Uno M; Makimoto G; Ninomiya K; Fujii M; Rai K; Ichihara E; Hotta K; Miyahara N; Tabata M; Maeda Y; Kiura K; Ohashi K
    Thorac Cancer; 2024 Jun; 15(17):1390-1394. PubMed ID: 38698706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of Chemotherapy Efficacy in Cervical Cancer via MAPK Pathway Inhibition by Osimertinib.
    Hu Y; Hu C
    Cancer Invest; 2024 May; 42(5):425-434. PubMed ID: 38818695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer.
    Conci N; De Giglio A; Sperandi F; Melotti B; Gelsomino F
    Chin Clin Oncol; 2024 Apr; 13(2):30. PubMed ID: 38600809
    [No Abstract]   [Full Text] [Related]  

  • 14. Transcriptomics coupled with proteomics reveals osimertinib-induced myocardial mitochondrial dysfunction.
    Yang H; Qiu S; Yao T; Liu G; Liu J; Guo L; Shi C; Xu Y; Ma J
    Toxicol Lett; 2024 Jun; 397():23-33. PubMed ID: 38734218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feiyiliu Mixture sensitizes EGFR
    Shi J; Hao S; Liu X; Li Y; Zheng X
    Front Pharmacol; 2023; 14():1093017. PubMed ID: 36744262
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
    Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
    Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
    Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.